Islet-cell carcinoma
| Islet-cell carcinoma | |
| Classification and external resources | |
| ICD-O: | Template:ICDO |
|---|---|
| MeSH | D018273 |
Overview
Islet cell carcinoma or nesidioblastoma is an uncommon cancer of the endocrine pancreas. It accounts for approximately 1.3% of pancreatic cancer.[1]. The term "nesidioblastoma" dates to at least 1938.[2] The term "nesidioblastoma" dates to at least 1938.[3]
Survival
Survival in islet cell carcinoma is highly dependent upon the degree of disease involvement; surgical cure is possible if the tumor is resected completely. Review articles using the Surveillance Epidemiology and End Results (SEER) national database have shown a median survival of about a decade for localized disease, six years for regional (confined to the region of the pancreas) and two years for those with distant disease.[4]
See also
References
- ↑ Yao JC, Eisner MP, Leary C; et al. (2007). "Population-based study of islet cell carcinoma". Ann. Surg. Oncol. 14 (12): 3492–500. doi:10.1245/s10434-007-9566-6. PMC 2077912. PMID 17896148. Unknown parameter
|month=ignored (help) - ↑ Laidlaw GF (1938). "Nesidioblastoma, the islet tumor of the pancreas". Am J Pathol. 14 (2): 125–34. PMC 1964945.
- ↑ Laidlaw GF (1938). "Nesidioblastoma, the islet tumor of the pancreas". Am J Pathol. 14 (2): 125–34. PMC 1964945. PMID 19970380.
- ↑ American Society of Clinical Oncology.